BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9200001)

  • 1. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
    Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
    J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
    Srivastava AK; MacFarlane G; Srivastava VP; Mohan S; Baylink DJ
    Calcif Tissue Int; 2001 Dec; 69(6):327-36. PubMed ID: 11800229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
    Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
    J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
    Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
    Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
    J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation.
    Brady JD; Ju J; Robins SP
    Clin Sci (Lond); 1999 Feb; 96(2):209-15. PubMed ID: 9918902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
    Cloos PA; Fledelius C
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
    Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
    J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.
    Rosenquist C; Fledelius C; Christgau S; Pedersen BJ; Bonde M; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2281-9. PubMed ID: 9799755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.